Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in Refractory Convulsive Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis and clinical EEGrafica of refractory convulsive status epilepticus~* Refractoriness of the drug I and II line~* Written informed consent from parents or legal guardian.~* Administration of rating scales in the risk of mortality (PIM III) and severity of SE (stess, status epilepticusseverity score) to be performed prior to randomization.~Exclusion Criteria:~* contraindications to the use of the medication/s in the study.~* pregnant or suspected pregnant.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- ketamine up to 100 mcg/kg/min (Type: EXPERIMENTAL): Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
- midazolam & thiopental & propofol (Type: ACTIVE_COMPARATOR): Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).